Clin2
NCT05717712Possibly a fitRecruiting

Study virus treatment for newly diagnosed DIPG in children

Oncolytic VirusDiffuse Intrinsic Pontine GliomaAdverse Drug Event

Part of Brain & nervous system, Cancer clinical trials.

This Phase 1 trial tests a type of cancer-fighting virus given directly into the tumor for children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The goal is to see if it can be delivered safely and to learn how the body responds to it.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
1 year to 18 years
Study type
Interventional

Who can take part

  • Your child is 1 to 18 years old and newly diagnosed with DIPG on MRI
  • No prior DIPG treatment has been started yet
  • Parents (or the patient, if able) can sign consent and your child can follow study visits and procedures
  • The tumor needs to be reachable for a needle biopsy and injection, without the virus going into the brain’s fluid spaces
  • Blood counts and organ tests must be strong enough for treatment (no serious organ failure, and no fever at baseline)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05717699Recruiting· Phase 1
Trial of a virus treatment for DIPG in children

This Phase 1 trial tests a lab-made cancer virus (Ad-TD-nsIL12) in children with DIPG whose tumor keeps growing after standard treatment. It mainly focuses on safety and how the treatment works, and it may help shrink or control the tumor by stimulating the immune system.

Beijing, Beijing Municipality
NCT04943848Recruiting· Phase 1
Vaccine plus immune treatment for newly diagnosed brain stem tumors

This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.

Orange, California
NCT06221553Recruiting· Phase 1
New CAR T-cell treatment for DIPG brain tumor

This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.

Bangkok, Pathumwan
NCT07680439Recruiting· Phase 2
CAR T cell therapy study for children with DIPG brain tumor

This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.

Los Angeles, California
NCT05956821Recruiting· Phase 1/Phase 2
Study drug for young people with recurring brain glioma

This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.

Miami, Florida
NCT07126990Enrolling by invitation· Phase 1/Phase 2
A new virus therapy for untreated high-grade glioma

This trial tests a modified virus that may help treat a type of brain cancer called high-grade glioma. It is for patients who have not yet had any treatment for their tumor.

Beijing, Chaoyang District

Hear when a new Oncolytic Virus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.